Publications
Detailed Information
Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Won | - |
dc.contributor.author | Yoon, Jung-Hwan | - |
dc.contributor.author | Kim, Jung-Ryul | - |
dc.contributor.author | Jang, In-Jin | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Kim, Yoon-Jun | - |
dc.contributor.author | Lee, Hyo-Suk | - |
dc.date.accessioned | 2012-05-24T06:01:00Z | - |
dc.date.available | 2012-05-24T06:01:00Z | - |
dc.date.created | 2020-12-21 | - |
dc.date.issued | 2009-07 | - |
dc.identifier.citation | Cancer Chemotherapy and Pharmacology, Vol.64 No.3, pp.497-507 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.other | 119279 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76415 | - |
dc.description.abstract | Hepatocellular carcinoma (HCC) is characterized by hypervascularity and chemoresistance. Protein kinase C (PKC) participates in cancer progression by enhancing anti-apoptotic signals, angiogenesis, and chemoresistance. Statins have a selective anti-cancer effect due to over-expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoAR) in cancer cells, but statins may also activate PKC. Thus, we hypothesized that simultaneous treatment with statin and PKC inhibitor might synergistically enhance their anti-tumor efficacies against HCCs. Hepatocellular carcinoma cell growth was assessed using MTS assays, apoptotic cell death by DAPI staining, and apoptotic signaling cascades were explored by immunoblotting. An in vivo model of HCC was established in C3H mice intradermally implanted with MH134 cells. Lovastatin and/or a PKC inhibitor (enzastaurin) was subsequently administered. Anti-tumor efficacies were evaluated by measuring tumor volumes and quantifying apoptotic cells and microvessel densities (MVD). Co-treatment with lovastatin and enzastaurin was found to synergistically suppress HCC cell growth in vitro. Lovastatin induced HCC cellular apoptosis by activating mitochondrial apoptotic signals, and although enzastaurin alone did not induce apoptosis, its addition significantly enhanced lovastatin-induced apoptosis. This enhanced apoptosis was attributed to increased caspase-9 activation in these cells. Moreover, tumor growth was significantly suppressed in mice co-treated with lovastatin and enzastaurin, and percentages of TUNEL-positive cells were significantly increased and MVDs were significantly decreased in those mice. Combinatorial treatment with statin and PKC inhibitor was found to enhance anti-tumor efficacy in vivo and in vitro. Further studies are warranted to prove anti-tumor efficacy of this potential therapy in human HCCs. | - |
dc.language | 영어 | - |
dc.language.iso | en | ko_KR |
dc.publisher | Springer Verlag | - |
dc.title | Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.identifier.doi | 10.1007/s00280-008-0897-1 | - |
dc.citation.journaltitle | Cancer Chemotherapy and Pharmacology | - |
dc.description.citedreference | Welch PA, 2007, J CLIN PHARMACOL, V47, P1138, DOI 10.1177/0091270007304775 | - |
dc.description.citedreference | Wu TT, 2007, CLIN CHIM ACTA, V382, P54, DOI 10.1016/j.cca.2007.03.018 | - |
dc.description.citedreference | Louafi S, 2007, CANCER, V109, P1384, DOI 10.1002/cncr.22532 | - |
dc.description.citedreference | Suzuki S, 2006, BBA-GEN SUBJECTS, V1760, P1552, DOI 10.1016/j.bbagen.2006.06.002 | - |
dc.description.citedreference | Carducci MA, 2006, J CLIN ONCOL, V24, P4092, DOI 10.1200/JCO.2005.05.3447 | - |
dc.description.citedreference | Myung SJ, 2006, HEPATO-GASTROENTEROL, V53, P266 | - |
dc.description.citedreference | Brady SC, 2005, MOL CELL BIOL, V25, P10543, DOI 10.1128/MCB.25.23.10543-10555.2005 | - |
dc.description.citedreference | Shi RX, 2005, CANCER RES, V65, P7815, DOI 10.1158/0008-5472.CAN-04-3875 | - |
dc.description.citedreference | Cafforio P, 2005, CARCINOGENESIS, V26, P883, DOI 10.1093/carcin/bgi036 | - |
dc.description.citedreference | Shibata MA, 2004, CARCINOGENESIS, V25, P1887, DOI 10.1093/carcin/bgh201 | - |
dc.description.citedreference | Wu JH, 2004, CANCER RES, V64, P6461 | - |
dc.description.citedreference | Kubota T, 2004, BIOCHEM PHARMACOL, V67, P2175, DOI 10.1016/j.bcp.2004.02.037 | - |
dc.description.citedreference | Graaf MR, 2004, J CLIN ONCOL, V22, P2388, DOI 10.1200/JCO.2004.02.027 | - |
dc.description.citedreference | Tanaka K, 2004, CLIN EXP PHARMACOL P, V31, P360 | - |
dc.description.citedreference | Keyes KA, 2004, CANCER CHEMOTH PHARM, V53, P133, DOI 10.1007/s00280-003-0713-x | - |
dc.description.citedreference | SKALETZROROWSKI A, 2004, SEMIN VASC MED, V4, P395 | - |
dc.description.citedreference | Llovet JM, 2003, LANCET, V362, P1907 | - |
dc.description.citedreference | Paragh G, 2003, ANTICANCER RES, V23, P3949 | - |
dc.description.citedreference | Lee HS, 2002, J CLIN ONCOL, V20, P4459, DOI 10.1200/JCO.2002.02.013 | - |
dc.description.citedreference | Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339 | - |
dc.description.citedreference | Selzer E, 2002, MELANOMA RES, V12, P201 | - |
dc.description.citedreference | Wong WWL, 2002, LEUKEMIA, V16, P508 | - |
dc.description.citedreference | Teicher BA, 2002, CANCER CHEMOTH PHARM, V49, P69, DOI 10.1007/s00280-001-0386-2 | - |
dc.description.citedreference | Goekjian PG, 2001, EXPERT OPIN INV DRUG, V10, P2117 | - |
dc.description.citedreference | Hentosh P, 2001, MOL CARCINOGEN, V32, P154 | - |
dc.description.citedreference | Higuchi H, 2001, J BIOL CHEM, V276, P38610 | - |
dc.description.citedreference | Parkin DM, 2001, INT J CANCER, V94, P153 | - |
dc.description.citedreference | Wong WWL, 2001, CLIN CANCER RES, V7, P2067 | - |
dc.description.citedreference | Kawata S, 2001, BRIT J CANCER, V84, P886, DOI 10.1054/bjoc.2001.1716 | - |
dc.description.citedreference | Yamashita Y, 2001, CANCER RES, V61, P1005 | - |
dc.description.citedreference | Kureishi Y, 2000, NAT MED, V6, P1004 | - |
dc.description.citedreference | Blais L, 2000, ARCH INTERN MED, V160, P2363 | - |
dc.description.citedreference | Yuen MF, 2000, HEPATOLOGY, V31, P330 | - |
dc.description.citedreference | Yoshiji H, 1999, CANCER RES, V59, P4413 | - |
dc.description.citedreference | Feleszko W, 1999, INT J CANCER, V81, P560 | - |
dc.description.citedreference | El-Serag HB, 1999, NEW ENGL J MED, V340, P745 | - |
dc.description.citedreference | Matsunaga T, 1998, JPN J CANCER RES, V89, P1276 | - |
dc.description.citedreference | Marais R, 1998, SCIENCE, V280, P109 | - |
dc.description.citedreference | Chou YY, 1997, J GASTROEN HEPATOL, V12, P569 | - |
dc.description.citedreference | Lee JY, 1996, J BIOL CHEM, V271, P13169 | - |
dc.description.citedreference | Thibault A, 1996, CLIN CANCER RES, V2, P483 | - |
dc.description.citedreference | GOSS VL, 1994, J BIOL CHEM, V269, P19074 | - |
dc.description.citedreference | CLEMENS MJ, 1992, J CELL SCI, V103, P881 | - |
dc.description.citedreference | BUCHWALD H, 1992, LANCET, V339, P1154 | - |
dc.description.citedreference | OBRIAN CA, 1989, CANCER RES, V49, P3215 | - |
dc.description.citedreference | LAI CL, 1988, CANCER, V62, P479 | - |
dc.description.citedreference | BEAL SL, 1984, DRUG METAB REV, V15, P173 | - |
dc.description.citedreference | NAKABAYASHI H, 1982, CANCER RES, V42, P3858 | - |
dc.description.citedreference | LITTMAN ML, 1966, CANCER CHEMOTH REP, V50, P25 | - |
dc.description.citedreference | SIPERSTEIN MD, 1964, CANCER RES, V24, P1108 | - |
dc.description.tc | 6 | - |
dc.identifier.wosid | 000267038900007 | - |
dc.identifier.scopusid | 2-s2.0-67349105662 | - |
dc.citation.endpage | 507 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 497 | - |
dc.citation.volume | 64 | - |
dc.identifier.sci | 000267038900007 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Yoon, Jung-Hwan | - |
dc.contributor.affiliatedAuthor | Jang, In-Jin | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.contributor.affiliatedAuthor | Kim, Yoon-Jun | - |
dc.contributor.affiliatedAuthor | Lee, Hyo-Suk | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | COENZYME-A REDUCTASE | - |
dc.subject.keywordPlus | TUMOR-SPECIFIC APOPTOSIS | - |
dc.subject.keywordPlus | P-GLYCOPROTEIN | - |
dc.subject.keywordPlus | ENDEMIC AREA | - |
dc.subject.keywordPlus | LIVER-TUMORS | - |
dc.subject.keywordPlus | PHASE-I | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | PATHWAY | - |
dc.subject.keywordAuthor | Hepatocellular carcinoma | - |
dc.subject.keywordAuthor | Statin | - |
dc.subject.keywordAuthor | Protein kinase C | - |
dc.subject.keywordAuthor | Apoptosis | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.